Close Menu

MRSA

Performed on the company's Safetube platform, GFC's Microscreen test uses DNA hybridization to detect biomarkers in methicillin-resistant Staphylococcus aureus.

The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals. 

The test, which simultaneously detects MRSA and Staphylococcus aureus, is designed to run on the company's Liat PCR point-of-care platform.

Scientists have shown that the test provides specific results in around one minute and can be adapted to detect several other pathogens.

To develop the test, the firm said it used a library of MRSA strains collected around the world, and included components that reduce false positive results.

Abaxis claims that Cepheid's PCR-based blood test for methicillin-resistant Staphylococcus aureus infringes its sample prep patents. In response, Cepheid has filed a counterclaim denying the alleged infringement and asking the court to find that Abaxis' patents are invalid.

Roche's test becomes the second PCR-based MRSA test approved for clinical use in the US, joining Cepheid's Xpert MRSA/SA nasal assay for the GeneXpert PCR platform.

Pages